Drug Trial Radar · NCT07087314
A Study of Anti-CD38 Monoclonal Antibody (SG301) Subcutaneous Injection in Children With Nephrotic Syndrome With Frequent Relapses or Steroid Dependence
Last checked: Nov 19, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Aug 25, 2025
Primary completion
Jul 9, 2028
Study completion Jul 9, 2029
Sponsor
- Lead sponsor
- Mao JianhuaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 years, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open - label study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of SG301 Subcutaneous injection in children with frequently relapsing or steroid - dependent nephrotic syndrome.
Conditions
- Nephrotic Syndrome in Children
Interventions
SG301 Subcutaneous injectionDrug
Subcutaneous injection every weeks (QW\*6),subsequently, administer it once every two weeks for a total of three times (Q2W\*3). The total number of doses is nine.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and rate of treatment-Emergent Adverse EventsTime frame: From baseline through study completion, an average of 1 year
- Relapse free survival rateTime frame: Average 1 year per subject
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Children's Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.